Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1200703 | PMC |
| http://dx.doi.org/10.1080/08998280.2005.11928037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of Anticoagulants in Reducing Stroke Risk Among Patients With Atrial Fibrillation.
Cureus
April 2024
General Medicine, Sri Venkateswara Institute of Medical Sciences (SVIMS) Sri Padmavathi Medical College for Women (SPMCW), Tirupati, IND.
Atrial fibrillation (AF) is a type of cardiac arrhythmia causing shortness of breath, lightheadedness, and palpitations. It may go unrecognized and asymptomatic among many patients. AF is not a potentially fatal arrhythmia; its hemodynamic, structural, and hemocoagulative effects have a significant impact on the standard of life, which can lead to various complications such as stroke.
View Article and Find Full Text PDFIncidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials.
Explor Res Clin Soc Pharm
June 2024
Physiology Department, Federal University of Sergipe (DFS/UFS).
Background: High-alert medication (HAM) is more predictable to cause significant harm to the patient, even when used as intended. The damage related to the HAM lead not only suffering to the patient, but also raise the additional costs associated with care.
Objective: Evaluate the incidence of drug-related adverse events related to the use of high-alert medications.
Argatroban as an Add-On to rtPA in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
J Clin Med
January 2024
Department of Internal Medicine, School of Health Sciences, University of Thessaly, 41334 Larissa, Greece.
Current treatment options for acute ischemic stroke, including intravenous thrombolysis (IVT) and mechanical thrombectomy, have undoubtedly revolutionized stroke care. The need for additional treatment options has brought into the light direct thrombin inhibitors (DTIs) and, specifically, argatroban as a promising candidate. However, there is uncertainty regarding the safety of adding argatroban to IVT, mainly due to the increased hemorrhagic risk.
View Article and Find Full Text PDFAntithrombotic prophylaxis following total hip arthroplasty: a level I Bayesian network meta-analysis.
J Orthop Traumatol
January 2024
Department of Orthopaedic, Trauma, and Reconstructive Surgery, BG Klinikum Bergmannstrost Halle, Halle (Saale), Germany.
Background: Several clinical investigations have compared different pharmacologic agents for the prophylaxis of venous thromboembolism (VTE). However, no consensus has been reached. The present investigation compared enoxaparin, fondaparinux, aspirin and non-vitamin K antagonist oral anticoagulants (NOACs) commonly used as prophylaxis following total hip arthroplasty (THA).
View Article and Find Full Text PDFOral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Cochrane Database Syst Rev
April 2023
Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada.
Article Synopsis
- Deep vein thrombosis (DVT) is a condition where a clot forms in the deep veins, usually in the leg, and if untreated, can lead to a dangerous pulmonary embolism (PE).
- The introduction of direct oral anticoagulants (DOACs), including oral direct thrombin inhibitors and oral factor Xa inhibitors, offers benefits over traditional treatments such as ease of use, predictable effects, and fewer drug interactions.
- This Cochrane Review aims to update the effectiveness and safety of DOACs compared to conventional anticoagulants for the long-term treatment of DVT, using data from various health databases and including only randomized controlled trials (RCTs) in the analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!